The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,632,561 in first-year total cost, median $816,281.
Most frequent study sections
- Clinical and Integrative Cardiovascular Sciences Study Section[CICS]1
- Special Emphasis Panel[ZCA1 RPRB-Z (O3)]1
Most frequent institutions
- MAYO CLINIC ROCHESTER1
- VANDERBILT UNIVERSITY MEDICAL CENTER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial1R01CA233610-01 | HERRMANN, JOERGRUDDY, KATHRYN JEAN | MAYO CLINIC ROCHESTER, MN | $951,993 | ZCA1 |
| 2019 | Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertension1R01HL141466-01A1 | MOSLEHI, JAVID J | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $680,568 | CICS |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.